Tardive Dyskinesia: Reversible and Irreversible
The long-term prognosis of tardive dyskinesia (TD) has been insufficiently studied. Symptoms are reversible in many patients, but an irreversible course is widely believed to be the expected outcome. This pessimistic view has led to the assumption that neuroleptics should not be used in patients with TD because these drugs will produce an inevitable aggravation of TD. To clarify this issue, 27 patients were serially evaluated over 5 years for changes in neuroleptic treatment, TD, and mental status. Ten patients were able to discontinue medications; 15 required continued low-dose neuroleptic therapy [average 223 mg/day chlorpromazine (CPZ) equivalents], and two needed high doses (1000–2000 mg/day CPZ equivalents) to control psychosis. The majority of patients improved by more than 50% in both treated and untreated groups. In 8 of 27 patients (29.6%) TD resolved; in 1 patient TD increased by 25%. Younger patients improved the most. Prognosis was most favorable if neuroleptics were discontinued, but improvement was still possible with low to moderate doses (less than 600 mg/day CPZ equivalents). The large majority of patients with schizophrenia or schizoaffective illness relapsed, and required continued drug treatment. TD must be evaluated over several years to monitor the resolving/persisting course. Control of psychosis and improvement of TD during low-dose neuroleptic treatment suggest the antipsychotic and neurological effects of neuroleptics may involve different thresholds or mechanisms of action.
KeywordsLithium Dopamine Dementia Schizophrenia Haloperidol
Unable to display preview. Download preview PDF.
- Ayd FJ (1977) Ethical and legal dilemmas posed by tardive dyskinesia. Int Drug Ther Newsletter 12: 29–36Google Scholar
- Baldessarini RJ (1977) Chemotherapy in psychiatry. Harvard University Press, Cambridge, pp 12–56Google Scholar
- Baldessarini RJ, Cole JO, Davis JM, Simpson G, Tarsy D, Gardos G, Preskorn SH (1980) Tardive dyskinesia; a task force report. American Psychiatric Association, Washington DCGoogle Scholar
- Casey DE (1984) Tardive dyskinesia and affective disorders. In: Gardos G, Casey DE (eds) Tardive dyskinesia and affective disorders. American Psychiatric Association, Washington DC, pp 1–20Google Scholar
- Casey DE, Gerlach J (1984) Tardive dyskinesia: management and new treatment. In: Stancer HC, Garfinkel PE, Rakoff VM (eds) Guidelines for the use of psychotropic drugs. Spectrum, New York, pp 183–203Google Scholar
- Chien CP, Cole JO (1973) Eighteen-months follow-up of tardive dyskinesia treated with various catecholamine-related agents. Psychopharmacol Bull 9: 38Google Scholar
- Gardos G, Cole JO (1982) Early dyskinesia: course, outcome, and prognosis. Proc Ann Meet Am Psychiatr Assoc 68 D: 171Google Scholar
- Guy W (1976) ECDEU assessment manual for psychopharmacology. US department of health, education, and welfare. US Government Printing Office, Washington DC, pp 534–537Google Scholar
- Levine J, Schooler N, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R (1980) Discontinuation of oral and depot fiuphenazine in schizophrenic patients after one year of continuous medication: a controlled study. In: Cattabeni F, Racagni G, Spano PF, Costa E (eds) Long-term effects of neuroleptics. Adv Biochem Psychopharmacol 24: 483–493Google Scholar
- Paulson GW (1968) “Permanent” or complex dyskinesias in the aged. Geriatrics 23:105–110Google Scholar
- Schönecker M (1957) Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation. Nervenarzt 28: 35Google Scholar